Update on the role of acyl-CoA: Cholesterol acyltransferase inhibitors in atherosclerosis

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 11, 2001, Pages 1655-1662

  Doshi, R ^a   Wu, J ^a   Fishelevich, R ^a   Rodriguez, A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acyl CoA:cholesterol acyltransferase (ACAT); Atherosclerosis; Foam cells; Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia

Indexed keywords

58 035; ACYL COENZYME A; ARYLMETHYLCARBAMOYL DERIVATIVE; ATORVASTATIN; AURANTIIN; AVASIMIBE; BIOFLAVONOID; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ACYLTRANSFERASE INHIBITOR 1; CHOLESTEROL ACYLTRANSFERASE INHIBITOR 2; CHOLESTEROL ESTER; CHYLOMICRON; CINNAMIC ACID; CYCLOALKYL DERIVATIVE; DIPHENYLUREA DERIVATIVE; ENZYME; HESPERIDIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROTEIN; NAPHTHYRIDINE DERIVATIVE; NEOHESPERIDIN DIHYDROCHALCONE; PHENYLENEDIAMINE DERIVATIVE; QUERCETIN; QUINAZOLINONE DERIVATIVE; RUTOSIDE; STATIN; TRIACYLGLYCEROL; TRITERPENOID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; FETUS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; INDUSTRIALIZATION; INTESTINE; LIPID ANALYSIS; LIVER CELL; MACROPHAGE; MALE; MORBIDITY; MORTALITY; NONHUMAN; PANCREAS; PROTEIN EXPRESSION; RISK FACTOR; TISSUE DISTRIBUTION;

EID: 0034752442     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.11.1655     Document Type: Article

References (36)

1. The pathogenesis of atherosclerosis: An update
2. The cholesteryl ester cycle in macrophage foam cells
3. Development of the lipid-rich core in human atherosclerosis
4. ACAT-2, a second mammalian acyl-CoA:cholesterol acyltransferase
5. Mammalian acyl-CoA:cholesterol acyltransferases
6. Acyl-CoenzymeA:cholesterol acyltransferase
7. Gene expression of acyl coenzyme A:cholesterol acyltransferase is upregulated in human monocytes during differentiation and foam cell formation
8. Expression of ACAT-1 protein in human atherosclerotic lesions and cultured human monocytes-macrophages
9. Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine
10. 2 among cells within liver, intestine, kidney, and adrenal of nonhuman primates
11. Novel effects of the acyl-Coenzyme A:cholesterol acyltransferase inhibitor 58-035 on foam cell development in primary human monocyte-derived macrophages
12. Anti-atherogenic effects of the acyl-CoA:cholesterol acyltransferase, Avasimibe (CI-1011), in cultured primary human macrophages
13. Disruption of the acyl-CoA:cholesterol acyltransferase gene in mice: Evidence suggesting multiple cholesterol esterification enzymes in mammals
14. ACAT inhibitors as antiatherosclerotic agents: Compounds and mechanisms
15. Avasimibe, treatment of lipoprotein disorders
16. The acyl-CoA:cholesterol acyltransferase (ACAT)-inhibitor avasimibe reduces atherosclerosis independently of its lipid-lowering effect in cholesterol-fed apoE3-Leiden transgenic mice
17. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits
18. The effects of atorvastatin, the ACAT inhibitor CI-1011, and progesterone on storage and secretion of cholesterol in human monocyte-derived macrophages
19. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia
20. An update of acyl-CoA:cholesterol acyltransferase inhibition in animal and human in vitro and in vivo models of atherosclerosis
21. Acyl coenzyme A: cholesterol acyltransferase types 1 and 2: Structure and function in atherosclerosis
22. Mammalian acyl-CoA:cholesterol acyltransferases
23. Acyl-coenzyme A:cholesterol acyltransferase 2
24. The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak in hamsters
25. ApoB100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011
26. Hypocholesterolemic effect of naringin associated with hepatic cholesterol regulating enzyme changes in rats
27. Cholesterol-lowering activity of naringenin via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase and acyl coenzyme-A:cholesterol acyltransferase in rats
28. Plasma and hepatic cholesterol and hepatic activities of 3-hydroxy-3-methyl-glutaryl-CoA reductase and acyl CoA:cholesterol transferase are lower in rats fed citrus peel extract or a mixture of citrus bioflavonoids
29. Activity-guided isolation of triterpenoid acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors from Ilex kudincha
30. Triterpenoid saponins from Ilex kudincha
31. 1 in macrophages
32. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1
33. Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice
34. Effects of the ACAT inhibitor CL 277, 082 on cholesterol metabolism in humans
35. Effect of the acyl-CoA:cholesterol acyltransferase inhibitor DUP128 on cholesterol absorption and serum cholesterol in humans
36. The tolerability, pharmacokinetics and lack of effect on plasma cholesterol of 447C88, an acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor with low bioavailability, in healthy volunteers